GlassScriptPhysician profile
Lisa Ganjhu
NPI 1710970702
$82,463.24
in general payments reported to CMS, 2019-2025
7 companies · $39K in 2025
The $39K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $3,041 · 2021: $121 · 2024: $26K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53K · Consulting Fee: $5,288 · Travel and Lodging: $3,148 · Food and Beverage: $2,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,232.50 |
| Consulting Fee | $5,287.50 |
| Travel and Lodging | $3,148.26 |
| Food and Beverage | $2,786.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $64,305.22 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $11,518.08 | 2019-2020 | |
| Gilead Sciences, INC. | $5,828.96 | 2019-2020 | |
| Qol Medical, LLC | $400.00 | 2020 | |
| Mirum Pharmaceuticals, INC. | $150.00 | 2025 | Livmarli |
| Intercept Pharmaceuticals, INC. | $139.58 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $121.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Ganjhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.